The Impact of Normal Aging Out on Continuity of Treatment among Children and Adolescents Living with HIV in the PEPFAR Supported Program in Kenya
Preprint
Abstract
Introduction To reduce HIV-related morbidity and mortality among children and adolescents living with HIV, defined as those 0-14 years old, continuity of treatment is critical. Treatment continuity estimates among children and adolescents living with HIV lag adults. We sought to understand how aging out among children and adolescents living with HIV in Kenya impacts continuity of treatment. Methods A retrospective cohort analysis was performed on de-identified individual-level data from the Kenya National Data Warehouse for all clients who initiated and/or received antiretroviral therapy between the periods of Oct 1, 2018 and Sep 30, 2022 (US Government fiscal years 2019-2022). Children and adolescents living with HIV previously on antiretroviral therapy and those newly initiating antiretroviral therapy were included in the analysis. Outcomes included aging out of the cohort after turning 15 years old, interruption in treatment, return to treatment, and remaining active on treatment. Results The study analyzed client-level data for four US Government fiscal years 2019-2022. The number of active children and adolescents living with HIV on treatment at the end of fiscal year 2019 was 44,628. This changed to 48,218, 48,262, and 44,780 representing 8%, 0%, and -7% cohort growth/loss at the end of fiscal years 2020, 2021 and 2022, respectively. Among those who were on treatment at the beginning of each fiscal year, aging-out accounted for 47%, 39%, and 28% of the total losses for the periods 2020, 2021 and 2022, respectively. Interruptions in treatment accounted for proportions ranging from 5-9% among those active on treatment. Among the newly-initiated on treatment within each fiscal year, aging-out proportions ranged from 3%-5%. Among those who returned to treatment in each fiscal year, the proportions who remained active at the end of the fiscal year varied from 72%-76%. Conclusions This analysis suggests that normal aging-out results in underestimation of HIV treatment continuity for children and adolescents living with HIV. Routine aging out analyses can inform programs on their true rates of interruptions in treatment, as they work to achieve epidemic control among children and adolescents living with HIV.Keywords
This publication has 9 references indexed in Scilit:
- Leveraging electronic medical records for HIV testing, care, and treatment programming in Kenya—the national data warehouse projectBMC Medical Informatics and Decision Making, 2023
- Children and young women in eastern and southern Africa are key to meeting 2030 HIV targets: time to accelerate actionThe Lancet HIV, 2023
- Factors associated with viral load suppression among orphans and vulnerable children and adolescents living with HIV in KenyaPLOS Global Public Health, 2023
- HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional studyBMC Infectious Diseases, 2021
- Factors affecting adherence to antiretroviral therapy among children and adolescents living with HIV in the Mbita Sub County Hospital, Homa Bay- KenyaAfrican Health Sciences, 2021
- Associations of transcription factor 7-Like 2 (TCF7L2) gene polymorphism in patients of type 2 diabetes mellitus from Khyber Pakhtunkhwa population of PakistanAfrican Health Sciences, 2021
- Healthcare retention and clinical outcomes among adolescents living with HIV after transition from pediatric to adult care: a systematic reviewBMC Public Health, 2020
- Viral suppression among children and their caregivers living with HIV in western KenyaJournal of the International AIDS Society, 2019
- HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South AfricaJournal of the International AIDS Society, 2018